Home › Urothelial (Transitional Cell) Carcinoma › Michigan › Lansing
Urothelial (Transitional Cell) Carcinoma clinical trials in Lansing, MI
4 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Lansing (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
RecruitingPhase 3
- University of Michigan Health - Sparrow Lansing, Lansing
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- University of Michigan Health - Sparrow Lansing, Lansing
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RecruitingPhase 2
- Karmanos Cancer Institute at McLaren Greater Lansing, Lansing
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Lansing
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Houston, TX18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- San Antonio, TX11 studies
- Boston, MA11 studies
- Austin, TX10 studies
Other studies in Lansing
- Lung Cancer11 studies
- Prostate Cancer10 studies
- Breast Cancer10 studies
- Non-Small Cell Lung Cancer9 studies
- Cancer (all types)6 studies
- Laryngeal Cancer5 studies
- Bladder Cancer5 studies
- Disorders of Excessive Somnolence5 studies
- Colorectal Cancer4 studies
- Kidney Cancer (Renal Cell Carcinoma)4 studies
- Colon Cancer4 studies
- Head and Neck Squamous Cell Carcinoma4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.